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I. Materials and Methods 
 
 
Unless noted in the specific procedure, reactions were performed in flame-dried 
glassware under argon atmosphere.  All metathesis reactions were carried out under air-free 
conditions in dry glassware in a Vacuum Atmospheres Glovebox filled with N2.  General solvents 
were purified by passing through solvent purification columns.  Commercially available 
substrates were used as received.  All solvents and substrates were sparged with Ar before 
bringing into the glovebox and filtered over basic alumina (Brockmann I) prior to use.  Reaction 
progress was monitored by thin-layer chromatography (TLC) using E. Merck silica gel 60 F254 
precoated plates (0.25 mm) and visualized by UV fluorescence quenching, potassium 
permanganate, or p-anisaldehyde staining.  Silicycle SiliaFlash P60 Academic Silica gel (particle 
size 0.040-0.063 mm) was used for flash chromatography.  Analytical chiral HPLC was 
performed with an Agilent 1100 Series HPLC utilizing a Chiralcel OD-H column (4.6 mm x 25 
cm) obtained from Daicel Chemical Industries, Ltd. with visualization at 254 nm.  Analytical 
SFC was performed with a Mettler SFC supercritical CO2 analytical chromatography system 
utilizing Chiralcel (IC) column (4.6 mm x 25 cm) obtained from Daicel Chemical Industries, Ltd. 
with visualization at 210 nm.  GC conversion data was obtained using an HP-5 capillary column 
with an Agilent 6850 FID gas chromatograph.  1H and 13C NMR spectra were recorded on a 
Varian Inova 500 spectrometer (500 MHz and 126 MHz, respectively), a Bruker AV III HD 
spectrometer equipped with a Prodigy liquid nitrogen temperature cryoprobe (400 MHz and 101 
MHz, respectively), or a Varian Mercury 300 spectrometer (300 MHz and 75 MHz, respectively) 
and are reported in terms of chemical shift relative to residual CHCl3 (δ 7.26 and δ 77.16 ppm, 
respectively).  Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm) 
(multiplicity, coupling constant (Hz), integration).  Abbreviations are used as follows: s = singlet, 
bs = broad singlet, d = doublet, t = triplet, q = quartet, quint = quintet, m = complex multiplet.  
Infrared (IR) spectra were recorded on a Perkin Elmer Paragon 1000 spectrometer using neat 
samples on ATR diamond, and are reported in frequency of absorption (cm–1).  High-resolution 
mass spectra HRMS were acquired from the Caltech Mass Spectral Facility using fast-atom 
bombardment (FAB+), electrospray ionization (TOF ES+) or electron impact (EI+).  Optical 
rotations were measured on a Jasco P-2000 polarimeter using a 100 mm path-length cell at 589 
nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 
 S4 
 
II. Experimental Procedures and Characterization Data 
 
1. Synthesis of D12-prostaglandin J2 (1): 
             Synthetic route:  
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Preparation of (S)-non-1-en-4-ol (8): 
 
 
 
Following the procedure by Yadav and co-workers1, to a stirred solution of TiCl4 (1.0 M solution 
in CH2Cl2, 2.5 mL, 2.5 mmol) in CH2Cl2 (50 mL) was added dried Ti(Oi-Pr)4 (2.24 mL,7.5 
mmol) at 0 °C under argon.  The solution was warmed to 23 ºC and stirred for 1 h, then Ag2O 
(1.15 g, 5.0 mmol) was added, and the mixture was stirred for 5 h with the exclusion of direct 
light by aluminum foil.  The reaction mixture was diluted with CH2Cl2 (80 mL) and (R)-
binaphthol (2.86 g, 10 mmol) was added at 23 ºC.  After 2 h, the reaction mixture was cooled to –
15 °C and hexanal (5.0 g, 50 mmol) and allyltributyltin (17 mL, 55 mmol) was added 
sequentially, then the reaction mixture was warmed to 0 °C.  After 8 h, saturated NaHCO3 (50 
mL) was added.  The aqueous phase was extracted with diethyl ether (2 × 250 mL).  The 
combined organic phases were washed with brine (1 × 200 mL), dried with anhydrous 
magnesium sulfate, filtered and concentrated under reduced pressure.  Purification by flash 
column chromatography on silica gel (SiO2, 15:1 hexanes/EtOAc) afforded compound 8 as a 
colorless oil (3.94 g, 55% yield, > 95% ee by Mosher-ester analysis). 
 
TLC (10:1 hexanes/EtOAc): Rf= 0.22 (p-anisaldehyde).  
1H NMR (400 MHz, CDCl3): δ 5.81 (dddd, J = 17.6, 9.4, 7.8, 6.5 Hz, 1H), 5.17 – 5.03 (m, 2H), 
3.62 (dtd, J = 8.0, 4.0, 2.4 Hz, 1H), 2.28 (dddt, J = 13.7, 6.8, 4.3, 1.3 Hz, 1H), 2.18 – 2.05 (m, 
1H), 1.74 (d, J = 3.6 Hz, 1H), 1.50 – 1.35 (m, 3H), 1.35 – 1.21 (m, 5H), 0.87 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz, CDCl3): δ 135.1, 118.1, 70.8, 42.0, 36.9, 32.0, 25.5, 22.7, 14.1. 
FTIR (ATR): 3355, 3077, 2956, 2929, 2859, 1641, 1467, 1435, 1378, 1124, 1027, 994, 911, 865, 
725 cm–1.  
HRMS (EI+, m/z): calc’d for C9H18O [M]+ 142.1352, found: 142.1372. [𝜶]𝑫𝟐𝟑: –7.2° (c = 1.0, CHCl3). 
 
Mosher-ester analysis of 8: 
 
 
 
To a stirred solution of 8 (21 mg, 0.15 mmol, 1.0 equiv) in CH2Cl2 (1.5 mL) in a 4 mL vial was 
added pyridine (0.1 mL, 1.24 mmol, 8.0 equiv) and (S)-(+)-Mosher chloride (100 mg, 0.40 mmol, 
2.7 equiv) at 25 °C.  After stirring for 2 h at the same temperature, the reaction mixture was 
diluted with CH2Cl2 (3 mL) and saturated NH4Cl solution (3 mL) was added.  The phases were 
separated, and the aqueous layer was extracted with CH2Cl2 (2 × 5 mL).  The combined organic 
extracts were concentrated after drying over magnesium sulfate.  (R)-MTPA ester 8a was 
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obtained through column chromatography (SiO2, 20:1 hexanes/EtOAc) as a colorless oil (50 mg, 
94 %). 
 
Compound 8b was prepared in the same manner and on the same scale as above using (R)-(−)-
Mosher chloride.  (S)-MTPA ester 8b was obtained through column chromatography (SiO2, 
hexanes/EtOAc, 20:1) as a colorless oil (51 mg, 96 %). 
 
(R)-MTPA ester 8a: 
TLC (10:1 hexanes/EtOAc): Rf= 0.57 (UV).  
1H NMR (400 MHz, CDCl3): δ 7.57 – 7.50 (m, 2H), 7.43 – 7.31 (m, 3H), 5.73 – 5.56 (m, 1H), 
5.14 (dq, J = 7.2, 5.7 Hz, 1H), 5.06 – 4.98 (m, 2H), 3.55 (q, J = 1.3 Hz, 3H), 2.35 (dddd, J = 6.2, 
5.0, 2.5, 1.3 Hz, 2H), 1.71 – 1.54 (m, 2H), 1.39 – 1.22 (m, 6H), 0.88 (t, J = 6.9 Hz, 3H). 
13C NMR (101 MHz, CDCl3): δ 166.4, 133.0, 132.5, 129.7, 128.4, 127.6, 123.5 (q, J = 288.6 Hz), 
118.4, 84.7 (q, J = 27.5 Hz), 76.7, 55.6, 38.2, 33.4, 31.6, 25.0, 22.6, 14.1. 
 19F NMR (282 MHz, CDCl3): δ –71.3. 
FTIR (ATR): 2955, 2934, 2861, 1743, 1643, 1612, 1506, 1451, 1258, 1166, 1121, 1081, 1020, 
993, 912, 823, 764, 732, 716, 696, 648 cm–1.  
HRMS (FAB+, m/z): calc’d for C19H26O3F3 [M+H]+ 359.1829, found: 359.1839. 
 
(S)-MTPA ester 8b: 
TLC (10:1 hexanes/EtOAc): Rf= 0.57 (UV).  
1H NMR (400 MHz, CDCl3): δ 7.58 – 7.52 (m, 2H), 7.43 – 7.34 (m, 3H), 5.76 (ddt, J = 16.1, 
10.4, 7.0 Hz, 1H), 5.16 (dt, J = 10.8, 5.2 Hz, 1H), 5.13 – 5.08 (m, 2H), 3.56 (q, J = 1.3 Hz, 3H), 
2.42 (ddt, J = 7.3, 6.1, 1.3 Hz, 2H), 1.65 – 1.49 (m, 2H), 1.27 – 1.10 (m, 6H), 0.84 (t, J = 6.9 Hz, 
3H). 
13C NMR (101 MHz, CDCl3): δ 166.4, 133.4, 132.6, 129.6, 128.4, 127.5, 123.5 (q, J = 288.6 Hz), 
118.5, 84.6 (q, J = 27.5 Hz), 76.7, 55.7, 38.5, 33.3, 31.6, 24.6, 22.6, 14.1. 
19F NMR (282 MHz, CDCl3): δ –71.3. 
FTIR (ATR): 2960, 2934, 2861, 1742, 1643, 1498, 1451, 1257, 1167, 1121, 1081, 1019, 992, 
912, 824, 764, 732, 717, 696, 648 cm–1.  
HRMS (FAB+, m/z): calc’d for C19H26O3F3 [M+H]+ 359.1829, found: 359.1845. 
 
Table S1. Comparison of 1H NMR data for (R)- and (S)-MTPA esters 
 
Proton (S)-MTPA ester 
5b 
(R)-MTPA 
ester 5a 
Dδ: (S)-(R) 
1 5.01 5.11 0.1 
2 5.64 5.76 0.12 
3 2.35 2.42 0.07 
4 5.14 5.16 0.02 
5 1.62 1.57 –0.05 
6-8 1.28 1.20 –0.08 
9 0.88 0.84 –0.04 
 
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 
 S7 
Preparation of 9: 
 
 
To a stirred solution of 8 (2.0 g, 14 mmol) in CH2Cl2 (60 mL) was added imidazole (2.86 g, 42 
mmol, 3.0 equiv) and TBSCl (4.22 g, 28 mmol, 2.0 equiv).  Saturated NH4Cl solution (50 mL) 
was added after stirring overnight.  The aqueous layer was extracted with CH2Cl2 (2 × 30 mL) 
and the combined organic phases were dried over anhydrous magnesium sulfate, filtered and 
concentrated under reduced pressure.  Column chromatography (SiO2, 20:1 hexanes/EtOAc) gave 
9 as a colorless oil (2.85 g, 79% yield). 
 
TLC (10:1 hexanes/EtOAc): Rf= 0.85 (p-anisaldehyde).  
1H NMR (400 MHz, CDCl3): δ 5.82 (ddt, J = 17.5, 10.4, 7.1 Hz, 1H), 5.08 – 4.99 (m, 2H), 3.68 
(quint, J = 5.7 Hz, 1H), 2.21 (dddt, J = 6.8, 5.3, 3.9, 1.3 Hz, 2H), 1.48 – 1.22 (m, 8H), 0.94 – 0.85 
(m, 12H), 0.05 (s, 3H), 0.05 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ 135.7, 116.7, 72.2, 42.1, 37.0, 32.2, 26.1, 25.2, 22.8, 18.3, 14.2, –
4.2, –4.4. 
FTIR (ATR): 2956, 2929, 2857, 1641, 1472, 1463, 1361, 1255, 1127, 1049, 1005, 939, 910, 834, 
807, 772, 664 cm–1.  
HRMS (EI+, m/z): calc’d for C15H31OSi [M+H–H2]+ 255.2138, found: 255.2174. [𝜶]𝑫𝟐𝟑: –15.7° (c = 1.0, CHCl3). 
 
Preparation of aldehyde 10: 
 
 
To a stirred solution of 9 (1.6 g, 6.25 mmol) in CH2Cl2 (30 mL) and MeOH (30 mL) was bubbled 
with O3 through a gas dispersion tube.  When the color of the solution turned blue, dimethyl 
sulfide (13.2 mL) and triethylamine (1.2 mL) was added.  The solution was stirred overnight and 
was concentrated under reduced pressure.  Column chromatography (SiO2, 20:1 hexenes/EtOAc) 
afforded 10 as a colorless oil (1.5 g, 93%) 
 
TLC (4:1 hexanes/EtOAc): Rf= 0.77 (p-anisaldehyde).  
1H NMR (400 MHz, CDCl3): δ 9.81 (td, J = 2.6, 0.7 Hz, 1H), 4.17 (quint, J = 5.8 Hz, 1H), 2.51 
(ddd, J = 5.7, 2.6, 0.7 Hz, 2H), 1.56 – 1.41 (m, 2H), 1.37 – 1.22 (m, 6H), 0.96 – 0.83 (m, 12H), 
0.07 (s, 3H), 0.05 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ 202.7, 68.4, 51.0, 38.0, 31.9, 25.9, 25.0, 22.7, 18.1, 14.2, –4.3, –
4.5. 
FTIR (ATR): 2956, 2929, 2857, 1713, 1472, 1361, 1253, 1096, 1050, 1005, 939, 834, 810, 774 
cm–1.  
HRMS (FAB+, m/z): calc’d for C14H31O2Si [M+H]+ 259.2088, found: 259.2088. [𝜶]𝑫𝟐𝟑: –3.0° (c = 1.0, CHCl3). 
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Preparation of enone (R)-6: 
 
Under argon atmosphere, a 500 mL flask was charged with (±)-6 (prepared through procedures 
by Reiser and co-workers2) (5.02 g, 25.4 mmol, 2.0 equiv) in CH2Cl2 (100 mL), p-methoxyphenol 
(1.57 g, 12.7 mmol, 1.0 equiv) and Cs2CO3 (1.22 g, 3.75 mmol, 0.296 equiv) was added and the 
solution was cooled to 0 ºC.  In another 100 mL flask, Pd2(dba)3•CHCl3 (131 mg, 0.127 mmol, 
0.01 equiv) and ligand (R,R)-DACH (306 mg, 0.44 mmol, 0.035 equiv) in CH2Cl2 (50 mL) was 
stirred until the initially purple solution turned yellow brown (4–5 min), and the catalyst solution 
was transferred to the 500 mL flask through a cannula.  The solvent was removed under reduced 
pressure after 2.5 h stirring at 0 ºC.  The residue was purified by flash chromatography 
(hexanes/EtOAc 9:1 to 6:1) to give (R)-6 (2.06 g, 41%, > 99% ee confirmed by chiral SFC 
analysis). 
 
TLC (4:1 hexanes/EtOAc): Rf= 0.4 (p-anisaldehyde).  
1H NMR (400 MHz, CDCl3): δ 7.59 (dd, J = 5.7, 2.4 Hz, 1H), 6.32 (dd, J = 5.7, 1.3 Hz, 1H), 5.70 
(dtd, J = 6.2, 2.3, 1.3 Hz, 1H), 2.82 (dd, J = 18.7, 6.4 Hz, 1H), 2.39 (dd, J = 18.7, 2.3 Hz, 1H), 
1.49 (s, 9H). 
13C NMR (101 MHz, CDCl3): δ 204.7, 158.7, 152.8, 137.2, 83.4, 74.3, 41.1, 27.8.  
FTIR (ATR): 2981, 2937, 1722, 1591, 1475, 1459, 1395, 1369, 1334, 1272, 1253, 1152, 1104, 
994, 840, 791 cm–1.  
HRMS (FAB+, m/z): calc’d for C10H15O4 [M+H]+ 199.0965, found: 199.0986. [𝛼]()*: +78.7° (c = 1.0, CHCl3). 
SFC Conditions: 3% IPA, 4.0 mL/min, Chiralcel IC column, λ = 210 nm, tR (min): major = 2.36, 
minor = 3.16 
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Preparation of 11: 
 
A 25 mL flask was flame dried and charged with CuBr•Me2S (144 mg, 0.70 mmol, 2.8 equiv) and 
LiCl (32 mg, 0.75 mmol, 3.0 equiv) in a nitrogen-filled glove box.  The flask was sealed with 
septum and brought out of glove box, and was heated under vacuum to remove residue water.  
Anhydrous THF (5 mL) was added, and the solution was vigorously stirred for 10 minutes at 23 
ºC until a yellow solution was formed.  At –78 ºC, allylmagnesium bromide (0.68 mL, 1.0 M 
solution in THF, 0.68 mmol, 2.7 equiv) was added slowly.  The reaction mixture was stirred at –
78 ºC for 1 hour and a solution of (R)-6 (149 mg, 0.75 mmol, 3.0 equiv) in THF (1 mL) was 
added slowly.  After 30 minutes stirring at the same temperature, a solution of 10 (65 mg, 0.25 
mmol, 1.0 equiv) in THF (1 mL) was added slowly.  The reaction was stirred for additional 2 
hours at –78ºC before a solution of saturated NH4Cl and NH3•H2O (10 mL, 9:1 NH4Cl/NH3•H2O) 
was added.  The biphasic solution was vigorously stirred until a homogeneous dark blue solution 
was formed in aqueous phase.  The phases were separated and the organic phase was washed with 
10 mL saturated NH4Cl solution.  The combined aqueous phase was extracted with Et2O (2 × 30 
mL).  The combined organic phase was dried with anhydrous magnesium sulfate, and was 
concentrated in vacuo.  The residue was purified by flash chromatography (SiO2, hexanes/EtOAc 
18:1) to give a mixture of diasteromers of the aldol product (82 mg, 0.22 mmol). 
 
In a 25 mL flask, the crude aldol product was dissolved in CH2Cl2 (6 mL) and cooled to –10 ºC.  
DMAP (403 mg, 3.3 mmol, 15.0 equiv) and MsCl (51 µL, 0.66 mmol, 3.0 equiv) were added 
sequentially.  The reaction mixture was slowly warmed to 23 ºC and was stirred for 12 h before 
diluted with 10 mL EtOAc and washed with 1 M HCl (10 mL).  The aqueous phase was extracted 
with EtOAc (2 × 20 mL).  The combined organic phase was dried with anhydrous magnesium 
sulfate, and was concentrated in vacuo.  The residue was purified by flash chromatography 
(hexanes/EtOAc 15:1) to give 11 (41 mg, 45% yield over 2 steps) as colorless liquid. 
 
TLC (9:1 hexanes/EtOAc): Rf= 0.25 (UV).  
1H NMR (400 MHz, CDCl3): δ 7.52 (ddd, J = 6.0, 2.6, 1.0 Hz, 1H), 6.60 (ddt, J = 8.3, 7.0, 1.3 
Hz, 1H), 6.33 (dd, J = 6.0, 1.8 Hz, 1H), 5.79 – 5.65 (m, 1H), 5.11 – 5.01 (m, 2H), 3.83 (quint, J = 
5.8 Hz, 1H), 3.50 (ddq, J = 8.4, 4.0, 2.0 Hz, 1H), 2.72 – 2.61 (m, 1H), 2.51 – 2.31 (m, 2H), 2.18 
(dddt, J = 14.3, 9.0, 7.9, 1.1 Hz, 1H), 1.53 – 1.11 (m, 8H), 0.96 – 0.79 (m, 12H), 0.05 (s, 3H), 
0.05 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ 196.5, 161.4, 138.5, 135.1, 134.3, 132.8, 117.8, 71.7, 43.1, 37.4, 
37.1, 32.0, 26.0, 25.1, 22.8, 18.2, 14.2, –4.2, –4.5. 
FTIR (ATR): 2955, 2928, 2856, 1705, 1656, 1582, 1472, 1360, 1252, 1207, 1127, 1050, 1005, 
915, 863, 834, 806, 773, 726, 663 cm–1.  
HRMS (TOF, ES+, m/z): calc’d for C22H39O2Si [M+H]+ 363.2714, found: 363.2711. [𝜶]𝑫𝟐𝟑: +85.3° (c = 1.0, CHCl3). 
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Preparation of 14: 
 
 
 
In a nitrogen-filled glovebox, cis-5-octen-1-ol (150 mg, 1.17 mmol, 8.0 equiv) was dissolved in 
toluene (2 mL) in a 50 mL Schlenk flask, and a solution of catalyst Ru-4 (9.9 mg, 11.7 µmol, 1 
mol%) in THF (0.7 mL) was added.  The Schlenk flask was sealed and brought out of the 
glovebox, and then connected to high vacuum.  The valve was gradually opened (Caution: open 
slowly and stir well to avoid splashing).  After 15 minutes stirring, the flask was refilled with 
argon and sealed, and was brought back into the glovebox.  The residue was diluted with THF 
(0.5 mL), and an aliquot was taken for GC analysis (conversion of homodimerization step was 
>98% by GC analysis).  A solution of 11 (53 mg, 0.146 mmol, 1.0 equiv) in THF (0.5 mL) was 
added into the Schlenk flask and an additional portion of catalyst Ru-4 (6.2 mg, 7.3 µmol, 5 
mol%) solution in THF (0.3 mL) was added.  The Schlenk flask was sealed and brought out of 
glovebox.  The reaction was stirred for 24 h at 40 ºC before a few drops of ethyl vinyl ether were 
added.  The solvent was removed under reduced pressure.  The residue was purified by flash 
chromatography (SiO2, hexanes/EtOAc 2:1) to give 14 (60 mg, 95%, >99:1 Z/E).   
 
TLC (3:1 hexanes/EtOAc): Rf= 0.23 (UV).  
1H NMR (400 MHz, CDCl3): δ 7.50 (ddd, J = 6.0, 2.6, 1.0 Hz, 1H), 6.59 (ddt, J = 8.3, 7.0, 1.3 
Hz, 1H), 6.33 (dd, J = 6.0, 1.8 Hz, 1H), 5.49 (dddt, J = 8.6, 7.2, 5.5, 1.5 Hz, 1H), 5.35 (dtt, J = 
11.0, 8.4, 1.6 Hz, 1H), 3.84 (quint, J = 5.9 Hz, 1H), 3.63 (t, J = 6.5 Hz, 2H), 3.46 (ddt, J = 11.0, 
4.2, 2.2 Hz, 1H), 2.63 (dddd, J = 13.8, 6.5, 4.2, 1.5 Hz, 1H), 2.50 – 2.34 (m, 2H), 2.17 (dddd, J = 
14.5, 9.4, 8.0, 1.3 Hz, 1H), 2.07 – 1.97 (m, 2H), 1.60 – 1.51 (m, 2H), 1.47 – 1.34 (m, 6H), 1.32 – 
1.19 (m, 5H), 0.95 – 0.81 (m, 12H), 0.05 (s, 3H), 0.05 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ 196.5, 161.8, 138.8, 135.0, 132.7, 132.5, 125.4, 71.7, 62.9, 43.6, 
37.5, 37.5, 32.5, 32.0, 30.7, 27.2, 26.0, 25.8, 25.1, 22.8, 18.2, 14.2, –4.2, –4.5. 
FTIR (ATR): 3443, 2956, 2928, 2856, 1703, 1652, 1580, 1472, 1360, 1251, 1206, 1127, 1048, 
1005, 975, 866, 834, 806, 773, 726, 664 cm–1.  
HRMS (TOF, ES+, m/z): calc’d for C26H47O3Si [M+H]+ 435.3289, found: 435.3298. [𝜶]𝑫𝟐𝟑: +83.5° (c = 1.0, CHCl3). 
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Preparation of D12-prostaglandin J2 (1): 
 
 
 
To a stirred solution of 14 (26 mg, 0.06 mmol, 1.0 equiv) in MeCN (0.3 mL) was added 
NMO•H2O (81 mg, 6 mmol, 10.0 equiv).  Tetrapropylammonium perruthenate (2.1 mg, 6 µmol, 
0.1 equiv) was added until NMO•H2O was fully dissolved, and the reaction was stirred at 23 ºC 
for 3 hours.  The solution was diluted with Et2O (5 mL), passed through a short pad of silica gel, 
concentrated and was subjected to the next reaction without further purification. 
 
The residue was dissolved in MeCN (1.0 mL) and cooled to 0 ºC.  A solution of hydrofluoric acid 
(48 wt. % in H2O, 0.2 mL) in MeCN (0.4 mL) was added dropwisely.  The solution was stirred in 
the same temperature for 30 min before saturated NaHCO3 solution (1.5 mL) and brine (1.5 mL) 
were added.  The aqueous phase was extracted with EtOAc (5 × 5 mL).  The combined organic 
phases were dried over magnesium sulfate, filtered and concentrated (not to dryness).  The 
residue was purified by flash chromatography (SiO2, CH2Cl2/MeOH 20:1) to give 1 (18 mg, 89% 
over 2 steps) as a colorless liquid. 
 
TLC (20:1 CH2Cl2/MeOH): Rf= 0.14 (UV).  
1H NMR (500 MHz, CDCl3): δ 7.57 (ddd, J = 6.0, 2.6, 1.0 Hz, 1H), 6.58 (ddt, J = 8.4, 7.2, 1.3 
Hz, 1H), 6.36 (dd, J = 6.0, 1.8 Hz, 1H), 5.54 – 5.38 (m, 2H), 3.86 (dtt, J = 7.9, 6.4, 4.0 Hz, 1H), 
3.47 (ddt, J = 9.5, 4.0, 2.1 Hz, 1H), 2.78 – 2.68 (m, 1H), 2.57 (dt, J = 14.8, 6.8 Hz, 1H), 2.52 – 
2.42 (m, 1H), 2.40 – 2.33 (m, 2H), 2.20 – 2.02 (m, 3H), 1.77 – 1.64 (m, 2H), 1.61 – 1.41 (m, 3H), 
1.40 – 1.24 (m, 5H), 0.90 (t, J = 6.8 Hz, 3H). 
13C NMR (126 MHz, CDCl3): δ 196.6, 177.3, 162.0, 139.8, 135.0, 131.8, 131.7, 126.2, 71.5, 43.9, 
37.3, 36.7, 33.1, 31.9, 30.6, 26.6, 25.4, 24.6, 22.8, 14.2. 
FTIR (ATR): 3445, 2960, 2929, 2858, 1699, 1646, 1579, 1463, 1406, 1265, 1237, 1135, 1084, 
1033, 842, 810, 734, 702 cm–1.  
HRMS (TOF, ES+, m/z): calc’d for C20H31O4 [M+H]+ 335.2217, found: 335.2223. [𝜶]𝑫𝟐𝟑: +99.5° (c = 0.2, CHCl3). 
 
Spectral data (1H NMR, 13C NMR, HRMS) matched with the published data.3 
 
 
 
 
 
 
 
 
 
 
O
Me
OTBS
OH 1. TPAP, NMO•H2O
   MeCN
2. HF (aq.), MeCN
(89% yield over 2 steps)
O
Me
OH
COOH
14 1
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 
 S12 
2. Synthesis of 15-deoxy-D12,14-prostaglandin J2 (2): 
Synthetic route: 
 
 
Preparation of 16: 
 
 
 
A 25 mL flask was flame dried and charged with CuBr•Me2S (195 mg, 0.95 mmol, 3.0 equiv) and 
LiCl (42 mg, 1 mmol, 3.2 equiv) in a nitrogen-filled glove box.  The flask was sealed with septum 
and brought out of glove box, and was heated under vacuum to remove residue water.  Anhydrous 
THF (10 mL) was added, and the solution was vigorously stirred for 10 minute at 23 ºC until a 
yellow homogeneous solution was formed.  At –78ºC, allylmagnesium bromide (0.9 mL, 1.0 M 
solution in THF, 0.9 mmol, 2.8 equiv) was added slowly.  The reaction mixture was stirred at –78 
ºC for 1 hour and a solution of (R)-6 (188 mg, 0.95 mmol, 3.0 equiv) in THF (1 mL) was added 
slowly.  After 30 minutes stirring at the same temperature, a solution of trans-2-octenal (15, 40 
mg, 0.32 mmol, 1.0 equiv) in THF (1 mL) was added slowly.  The reaction was stirred for 
additional 2 hours at –78 ºC before a solution of saturated NH4Cl and NH3•H2O (10 mL, 9:1 
NH4Cl/NH3•H2O) was added.  The biphasic solution was vigorously stirred until a homogeneous 
dark blue solution was formed in aqueous phase.  The phases were separated and the organic 
phase was washed with 10 mL saturated NH4Cl solution.  The combined aqueous phase was 
extracted with Et2O (2 × 30 mL).  The combined organic phase was dried with anhydrous 
magnesium sulfate, and was concentrated in vacuo.  The residue was purified by flash 
chromatography (SiO2, hexanes/EtOAc 15:1) to give a mixture of diasteromers of the aldol 
products (57 mg, 0.23 mmol). 
 
In a 25 mL flask, the crude aldol product was dissolved in CH2Cl2 (6 mL) and cooled to –10 ºC.  
DMAP (421 mg, 3.45 mmol, 15.0 equiv) and MsCl (53 µL, 0.69 mmol, 3.0 equiv) was added 
sequentially.  The reaction mixture was slowly warmed to 23 ºC and was stirred for 2 h before 
O
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O
Me
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Ru-4 (1 mol%)
   toluene, 23 ºC, 2 torr
then 16, Ru-4 (5 mol%)
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(93% yield, >99:1 Z/E, 87% ee)
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diluted with 10 mL EtOAc and washed with 1 M HCl (10 mL).  The aqueous phase was extracted 
with EtOAc (2 × 20 mL).  The combined organic phase was dried with anhydrous magnesium 
sulfate, and was concentrated in vacuo.  The residue was purified by flash chromatography (SiO2, 
hexanes/EtOAc 15:1) to give 16 (30 mg, 41% yield over 2 steps, 88% ee by chiral HPLC 
analysis) as a colorless liquid. 
 
TLC (4:1 hexanes/EtOAc): Rf= 0.56 (UV).  
1H NMR (300 MHz, CDCl3): δ 7.50 (ddd, J = 6.0, 2.6, 1.0 Hz, 1H), 6.95 (dt, J = 10.7, 1.2 Hz, 
1H), 6.35 (dd, J = 6.0, 1.8 Hz, 1H), 6.33 – 6.15 (m, 2H), 5.81 – 5.64 (m, 1H), 5.11 – 5.01 (m, 
2H), 3.60 (ddq, J = 8.5, 4.1, 1.9 Hz, 1H), 2.73 – 2.58 (m, 1H), 2.24 (dddd, J = 13.4, 9.7, 6.8, 1.5 
Hz, 3H), 1.54 – 1.37 (m, 2H), 1.38 – 1.22 (m, 4H), 0.89 (t, 3H, J = 6.9 Hz). 
13C NMR (75 MHz, CDCl3): δ 197.5, 160.6, 147.1, 135.4, 134.9, 134.3, 131.8, 125.7, 117.8, 43.2, 
37.4, 33.6, 31.5, 28.6, 22.6, 14.1. 
FTIR (ATR): 2954, 2928, 2859, 1699, 1642, 1581, 1458, 1344, 1194, 994, 918, 829, 734 cm–1.  
HRMS (FAB+, m/z): calc’d for C16H21O [M+H–H2]+ 229.1586, found: 229.1581. [𝜶]𝑫𝟐𝟑: +65.4° (c = 1.0, CHCl3). 
HPLC Conditions: 10% IPA, 1.0 mL/min, Chiralcel OD-H column, λ = 254 nm, tR (min): major = 
5.37, minor = 6.44 
 
 
 
Preparation of 17: 
 
 
 
In a nitrogen-filled glovebox, cis-5-octen-1-ol (113 mg, 0.88 mmol, 8.0 equiv) was dissolved in 
toluene (1 mL) in a 50 mL Schlenk flask and a solution of catalyst Ru-4 (7.5 mg, 8.8 µmol, 1 
O
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OHcis-5-octen-1-olRu-4 (1 mol%)
   toluene, 23 ºC, 2 torr
then 16, Ru-4 (5 mol%)
THF, 40 ºC
(93% yield, >99:1 Z/E, 87% ee)
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mol%) in THF (0.6 mL) was added.  The Schlenk flask was sealed and brought out of the 
glovebox, and then connected to high vacuum.  The valve was gradually opened (Caution: open 
slowly and stir well to avoid splashing).  After 15 minutes stirring, the flask was refilled with 
argon and sealed, and was brought back into the glovebox.  The residue was diluted with THF 
(0.5 mL), and an aliquot was taken for GC analysis (conversion of homodimerization step was 
>98% by GC analysis).  A solution of 16 (25 mg, 0.11 mmol, 1.0 equiv) in THF (0.5 mL) was 
added into the Schlenk flask and an additional portion of catalyst Ru-4 (4.6 mg, 5.5 µmol, 5 
mol%) solution in THF (0.2 mL) was added.  The Schlenk flask was sealed and brought out of 
glovebox.  The reaction was stirred for 24 h at 40 ºC before a few drops of ethyl vinyl ether were 
added.  The solvent was removed under reduced pressure.  The residue was purified by flash 
chromatography (SiO2, hexanes/EtOAc 2:1) to give 17 (31 mg, 93%, >99:1 Z/E, 87% ee by chiral 
HPLC analysis).   
 
TLC (4:1 hexanes/EtOAc): Rf= 0.2 (UV).  
1H NMR (400 MHz, CDCl3) δ 7.48 (ddd, J = 6.0, 2.6, 1.0 Hz, 1H), 6.95 (dt, J = 11.0, 1.3 Hz, 
1H), 6.35 (dd, J = 6.0, 1.8 Hz, 1H), 6.34 – 6.19 (m, 2H), 5.52 – 5.44 (m, 1H), 5.38 – 5.30 (m, 
1H), 3.63 (t, J = 6.5 Hz, 2H), 3.60 – 3.55 (m, 1H), 2.60 (dddd, J = 14.0, 6.2, 4.3, 1.4 Hz, 1H), 
2.30 (dtd, J = 14.4, 8.6, 1.2 Hz, 1H), 2.25 – 2.17 (m, 2H), 2.01 (qd, J = 7.3, 1.4 Hz, 2H), 1.59 – 
1.49 (m, 2H), 1.48 – 1.37 (m, 5H), 1.34 – 1.29 (m, 4H), 0.89 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3): δ 197.6, 160.9, 147.0, 135.4, 135.3, 132.6, 131.8, 125.8, 125.3, 
62.9, 43.7, 33.6, 32.5, 31.5, 30.9, 28.6, 27.2, 25.8, 22.6, 14.2. 
FTIR (ATR): 3445, 2960, 2930, 2862, 1690, 1629, 1580, 1447, 1264, 1207, 1054, 979, 732 cm–1.  
HRMS (TOF, ES+, m/z): calc’d for C20H31O2 [M+H]+ 303.2319, found: 303.2320. [𝜶]𝑫𝟐𝟑: +115.8° (c = 0.5, CHCl3). 
HPLC Conditions: 10% IPA, 1.0 mL/min, Chiralcel OD-H column, λ = 254 nm, tR (min): major = 
10.12, minor = 13.57 
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Preparation of 15-deoxy-D12,14-prostaglandin J2 (2): 
 
 
 
To a stirred solution of 17 (14 mg, 0.046 mmol, 1.0 equiv) in MeCN (0.5 mL) was added 
NMO•H2O (65 mg, 0.46 mmol, 10.0 equiv).  Tetrapropylammonium perruthenate (1.7 mg, 4.6 
µmol, 0.1 equiv) was added until NMO•H2O was fully dissolved and the reaction was stirred at 
23 ºC for 3 hours.  The reaction mixture was stirred for 3 hours and the solvent was removed in 
vacuo.  The residue was loaded onto a silica gel column, flushed with CH2Cl2 then 
CH2Cl2/MeOH (20:1).  15-deoxy-D12,14-prostaglandin J2 (2) was obtained as a colorless oil (10 mg, 
68% yield). 
 
TLC (100% EtOAc): Rf= 0.70 (UV). 
1H NMR (400 MHz, CDCl3): δ 7.47 (ddd, J = 6.0, 2.6, 1.0 Hz, 1H), 6.95 (d, J = 11.0 Hz, 1H), 
6.38 – 6.35 (m, 1H), 6.33 – 6.20 (m, 2H), 5.50 – 5.33 (m, 2H), 3.59 (ddd, J = 8.4, 4.1, 2.2 Hz, 
1H), 2.59 (m, 1H), 2.36 – 2.19 (m, 5H), 2.05 (q, J = 7.3 Hz, 2H), 1.68 (quint, J = 7.5 Hz, 2H), 
1.50 – 1.41 (m, 2H), 1.34 – 1.28 (m, 4H), 0.90 (t, J = 7.0 Hz, 3H). 
13C NMR (101 MHz, CDCl3): δ 197.6, 177.9, 160.8, 147.2, 135.5, 135.1, 131.9, 131.5, 126.2, 
125.8, 43.6, 33.6, 33.2, 31.6, 30.8, 28.6, 26.7, 24.6, 22.6, 14.2. 
FTIR (ATR): 2960, 2928, 2850, 1708, 1692, 1629, 1456, 1265, 1207, 978, 734, 703 cm–1.  
HRMS (TOF, ES+, m/z): calc’d for C20H29O3 [M+H]+ 317.2111, found: 317.2127. [𝜶]𝑫𝟐𝟑: +106.2° (c = 0.2, CHCl3). 
 
Spectral data (1H NMR, 13C NMR, HRMS) matched with the published data.3,4 
 
3. Synthesis of D12-prostaglandin J3 (3): 
Synthetic route: 
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Preparation of 18: 
 
 
 
Procedures are same as Dai and co-workers.5  1,3-dithiane (1.2 g, 10 mmol, 1.0 equiv) was 
dissolved in THF (15 mL) and cooled to –78 ºC.  n-BuLi (2.5 M solution in hexanes, 4.4 mL, 11 
mmol, 1.1 equiv) was added and the solution was stirred at the same temperature for 15 min, then 
warmed up to –20 °C and stirred for 1 h.  The reaction mixture was cooled down to –78 °C and 
(R)-epichlorohydrin (1.1 mL, 14 mmol, 1.4 equiv) was added dropwisely.  The reaction mixture 
was stirred at –78 °C for 1 h, then slowly warmed to 23 ºC and stirred overnight and then cooled 
to –40 ºC.  In another flame-dried flask, vinyl magnesium bromide (28 mL, 1.0 M in THF, 28 
mmol, 2.8 equiv) was added to a stirred solution of CuBr•Me2S (124 mg, 0.6 mmol, 0.06 equiv) 
in THF (20 mL), and the resulting solution was transferred into the reaction mixture through a 
cannula at –40 ºC.  The reaction mixture was slowly warmed to 23 ºC and stirred overnight 
before 1 M HCl (50 mL) was added.  The biphasic mixture was extracted with EtOAc (3 × 50 
mL).  The combined organic extract was washed with brine, dried with anhydrous magnesium 
sulfate, filtered and concentrated under reduced pressure.  The residue was purified by flash 
chromatography (SiO2, hexanes/EtOAc = 9:1) to afford 18 (1.20 g, 58% yield) as colorless liquid. 
 
TLC (4:1 hexanes/EtOAc): Rf= 0.27 (UV).  
1H NMR (400 MHz, CDCl3): δ 5.89 – 5.72 (m, 1H), 5.14 (m, 2H), 4.26 (dd, J = 7.8, 6.6 Hz, 1H), 
4.02 – 3.94 (m, 1H), 2.96 – 2.78 (m, 4H), 2.33 – 2.24 (m, 1H), 2.24 – 2.16 (m, 1H), 2.16 – 2.06 
(m, 1H), 2.01 (d, J = 4.2 Hz, 1H), 1.95 – 1.82 (m, 3H). 
13C NMR (101 MHz, CDCl3): δ 134.2, 118.7, 67.6, 44.3, 42.2, 42.1, 30.5, 30.2, 26.0. 
FTIR (ATR): 3413, 3073, 2930, 2900, 2851, 2827, 1640, 1422, 1275, 1242, 1172, 1123, 1062, 
1027, 993, 908, 866, 770, 664 cm–1.  
HRMS (FAB+, m/z): calc’d for C9H16OS2 [M]+ 204.0637, found: 204.0657. [𝜶]𝑫𝟐𝟑: +22.2° (c = 1.0, CHCl3). 
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Preparation of 19: 
 
 
 
To a stirred solution of 18 (0.70 g, 3.43 mmol) in CH2Cl2 (20 mL) was added imidazole (0.70 g, 
10.29 mmol, 3.0 equiv) and TBSCl (1.03 g, 6.86 mmol, 2.0 equiv).  Saturated NH4Cl solution (20 
mL) was added after stirring overnight.  The aqueous layer was extracted with CH2Cl2 (3 × 20 
mL) and the combined organic phase was dried over anhydrous magnesium sulfate, filtered and 
concentrated under reduced pressure.  Column chromatography (SiO2, 20:1 hexanes/EtOAc) gave 
19 as a colorless oil (1.04 g, 95% yield). 
 
TLC (10:1 hexanes/EtOAc): Rf= 0.54 (UV).  
1H NMR (400 MHz, CDCl3): δ 5.83 – 5.71 (m, 1H), 5.07 – 5.00 (m, 2H), 4.08 (dd, J = 7.8, 6.9 
Hz, 1H), 4.00 (qd, J = 6.2, 4.9 Hz, 1H), 2.92 – 2.75 (m, 4H), 2.23 (dtt, J = 7.5, 5.1, 1.3 Hz, 2H), 
2.09 (dddt, J = 10.6, 5.0, 4.2, 2.8 Hz, 1H), 1.93 – 1.83 (m, 1H), 1.83 – 1.78 (m, 2H), 0.88 (s, 9H), 
0.09 (s, 3H), 0.07 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ 134.3, 117.6, 68.1, 44.1, 42.3, 42.3, 30.7, 30.1, 26.2, 26.0, 18.2, –
4.3, –4.5. 
FTIR (ATR): 2952, 2928, 2896, 2855, 1640, 1472, 1423, 1360, 1254, 1185, 1070, 1004, 940, 
915, 834, 808, 773, 666 cm–1.  
HRMS (FAB+, m/z): calc’d for C15H31OS2Si [M+H]+ 319.1580, found: 319.1583. [𝜶]𝑫𝟐𝟑: +41.1° (c = 1.0, CHCl3). 
 
 
Preparation of aldehyde 20: 
 
 
 
To a solution of 19 (636 mg, 2 mmol, 1.0 equiv) in MeCN/H2O (20 mL, 9:1) was added CaCO3 
(1.0 g, 10 mmol, 5.0 equiv) and MeI (1.87 mL, 30 mmol, 15.0 equiv).  The reaction mixture was 
stirred at 50 ºC for 6 h, then diluted with water (20 mL) and extracted with EtOAc (3 × 20 mL).  
The combined organic extract was dried over anhydrous magnesium sulfate, filtered and 
concentrated under reduced pressure.  The residue was purified by column chromatography 
(SiO2, 20:1 hexanes/EtOAc) to afford 20 (430 mg, 94%) as a colorless liquid. 
 
TLC (10:1 hexanes/EtOAc): Rf= 0.45 (p-anisaldehyde).  
1H NMR (400 MHz, CDCl3): δ 9.80 (td, J = 2.4, 0.8 Hz, 1H), 5.78 (ddt, J = 16.5, 10.8, 7.2 Hz, 
1H), 5.12 – 5.03 (m, 2H), 4.26 (quint, J = 5.9 Hz, 1H), 2.55 – 2.52 (m, 2H), 2.30 (ddt, J = 7.1, 
6.0, 1.2 Hz, 2H), 0.87 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ 202.3, 133.9, 118.3, 67.9, 50.5, 42.5, 25.9, 18.1, –4.2, –4.7. 
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FTIR (ATR): 2955, 2929, 2890, 2857, 1726, 1641, 1472, 1361, 1254, 1098, 1041, 1005, 915, 
834, 810, 774, 680 cm–1.  
HRMS (FAB+, m/z): calc’d for C12H25O2Si [M+H]+ 229.1618, found: 229.1629. [𝜶]𝑫𝟐𝟑: +22.0° (c = 1.0, CHCl3). 
 
Preparation of aldehyde 21: 
 
 
 
In a nitrogen-filled glovebox, 20 (146 mg, 0.64 mmol, 1 equiv) and cis-3-hexene (215 mg, 2.56 
mmol, 4 equiv) were weighed into a 4 mL vial.  A solution of catalyst Ru-4 (22 mg, 25.6 µmol, 4 
mol%) in THF (1.5 mL) was transferred into the vial.  The reaction mixture was stirred for 1 h at 
23 ºC.  An aliquot was taken for GC analysis to monitor the conversion.  Then the vial was 
brought out of the glovebox, concentrated in vacuo.  The residue was purified by column 
chromatography (SiO2, hexanes/EtOAc 20:1) to afford 21 (145 mg, 88%) as a colorless liquid.   
 
TLC (10:1 hexanes/EtOAc): Rf= 0.45 (p-anisaldehyde).  
1H NMR (400 MHz, CDCl3): δ 9.80 (t, J = 2.4 Hz, 1H), 5.54 – 5.41 (m, 1H), 5.32 (dtt, J = 10.8, 
7.5, 1.6 Hz, 1H), 4.22 (dq, J = 7.1, 5.7 Hz, 1H), 2.51 (dd, J = 5.8, 2.4 Hz, 2H), 2.38 – 2.17 (m, 
2H), 2.10 – 1.92 (m, 2H), 0.96 (t, J = 7.5 Hz, 3H), 0.87 (s, 9H), 0.08 (s, 3H), 0.06 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ 202.4, 134.8, 123.7, 68.3, 50.6, 35.7, 25.9, 20.9, 18.1, 14.3, –4.2, 
–4.7. 
FTIR (ATR): 2957, 2930, 2890, 2857, 1726, 1472, 1361, 1253, 1096, 1005, 938, 834, 811, 774, 
680 cm–1.  
HRMS (FAB+, m/z): calc’d for C14H27O2Si [M+H-H2]+ 255.1774, found: 255.1780. [𝜶]𝑫𝟐𝟑: +22.0° (c = 0.4, C6H6). 
 
 
Preparation of 22: 
 
 
 
A 25 mL flask was flame dried and charged with CuBr•Me2S (142 mg, 0.69 mmol, 3.0 equiv) and 
LiCl (31 mg, 0.74 mmol, 3.2 equiv) in a nitrogen-filled glove box.  The flask was sealed with 
septum and brought out of glove box, and was heated under vacuum to remove residue water.  
Anhydrous THF (5 mL) was added, and the solution was vigorously stirred for 10 minute at 23 ºC 
cis-3-hexene
Ru-4 (4 mol%)
THF
(88% yield, >99:1 Z/E)
OTBS
O
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O
Me
20 21
O
BocO
1. CuBr•Me2S, LiCl, allylMgBr
THF, –78 ºC
then 21, THF, –78 ºC
2. MsCl, DMAP, CH2Cl2
   –10 ºC to 23 ºC
(40% yield over 2 steps)(R)-6
O OTBS
Me
22
OTBS
O
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until a yellow solution was formed.  At –78ºC, allylmagnesium bromide (0.65 mL, 1.0 M solution 
in THF, 0.65 mmol, 2.8 equiv) was added slowly.  The reaction mixture was stirred at –78 ºC for 
1 hour and a solution of (R)-6 (137 mg, 0.69 mmol, 3.0 equiv) in THF (1 mL) was added slowly.  
After 30 minutes stirring at the same temperature, a solution of 21 (59 mg, 0.23 mmol, 1.0 equiv) 
in THF (1 mL) was added slowly.  The reaction was stirred for additional 2 hours at –78 ºC 
before a solution of saturated NH4Cl and NH3•H2O (10 mL, 9:1 NH4Cl/NH3•H2O) was added.  
The biphasic solution was vigorously stirred until a homogeneous dark blue solution was formed 
in aqueous phase.  The phases were separated and the organic phase was washed with 10 mL 
saturated NH4Cl solution.  The combined aqueous phase was extracted with Et2O (2 × 30 mL).  
The combined organic phase was dried with anhydrous magnesium sulfate, and was concentrated 
in vacuo.  The residue was purified by flash chromatography (SiO2, hexanes/EtOAc 18:1) to give 
a mixture of diasteromers of the aldol products (50 mg, 0.13 mmol). 
 
In a 25 mL flask, the crude aldol product was dissolved in CH2Cl2 (5 mL) and cooled to –10 ºC.  
DMAP (242 mg, 2.0 mmol, 15.0 equiv) and MsCl (31 µL, 0.4 mmol, 3.0 equiv) was added 
sequentially.  The reaction mixture was slowly warmed to 23 ºC and was stirred for 12 h before 
diluted with 10 mL EtOAc and washed with 1 M HCl (5 mL).  The aqueous phase was extracted 
with EtOAc (2 × 10 mL).  The combined organic phase was dried with anhydrous magnesium 
sulfate, and was concentrated in vacuo.  The residue was purified by flash chromatography 
(hexanes/EtOAc 15:1) to give 22 (33 mg, 40% yield over 2 steps) as a colorless liquid. 
 
TLC (4:1 hexenes/EtOAc): Rf= 0.67 (UV).  
1H NMR (400 MHz, CDCl3): δ 7.51 (ddd, J = 6.1, 2.6, 1.0 Hz, 1H), 6.61 (ddt, J = 9.0, 8.0, 1.3 
Hz, 1H), 6.33 (dd, J = 6.0, 1.8 Hz, 1H), 5.79 – 5.64 (m, 1H), 5.52 – 5.41 (m, 1H), 5.42 – 5.30 (m, 
1H), 5.10 – 5.01 (m, 2H), 3.88 (quint, J = 6.0 Hz, 1H), 3.48 (ddd, J = 8.8, 4.0, 2.0 Hz, 1H), 2.72 – 
2.61 (m, 1H), 2.46 – 2.38 (m, 2H), 2.30 – 2.11 (m, 3H), 2.05 – 1.95 (m, 2H), 0.93 (t, J = 7.5 Hz, 
3H), 0.87 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ 196.4, 161.4, 138.6, 135.1, 134.4, 134.1, 132.7, 124.4, 117.7, 
71.7, 43.1, 37.1, 36.9, 35.3, 26.0, 20.9, 18.2, 14.3, –4.4, –4.4. 
FTIR (ATR): 2957, 2929, 2894, 2856, 1706, 1657, 1582, 1472, 1366, 1253, 1148, 1083, 1005, 
966, 915, 835, 808, 775 cm–1.  
HRMS (FAB+, m/z): calc’d for C22H37O2Si [M+H]+ 361.2557, found: 361.2576. [𝜶]𝑫𝟐𝟑: +122.3° (c = 1.0, CHCl3). 
 
Preparation of 23 using Ru-4: 
 
 
 
In a nitrogen-filled glovebox, cis-5-octen-1-ol (72 mg, 0.55 mmol, 6.7 equiv) was dissolved in 
toluene (1 mL) in a 50 mL Schlenk flask and a solution of catalyst Ru-4 (4.7 mg, 5.6 µmol, 1 
mol%) in THF (0.6 mL) was added.  The Schlenk flask was sealed and brought out of the 
23
(44% yield)
cis-5-octen-1-ol
Ru-4 (1 mol%)
   toluene, 23 ºC, 2 torr
then 22, Ru-4 (5 mol%)
THF, 23 ºCO OTBS
Me
O OTBS
Me
OH
O
OTBS
+
24
(31% yield)
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glovebox, and then connected to high vacuum.  The valve was gradually opened (Caution: open 
slowly and stir well to avoid splashing).  After 15 minutes stirring, the flask was refilled with 
argon and sealed, and was brought back into the glovebox.  The residue was diluted with 0.5 mL 
THF, and an aliquot was taken for GC analysis (conversion of homodimerization step was >98% 
by GC analysis).  A solution of 22 (30 mg, 0.083 mmol, 1 equiv) in 0.5 mL THF was added into 
the Schlenk flask and an additional 0.4 mL of catalyst solution with Ru-4 (2.9 mg, 3.5 µmol, 5 
mol%) was added.  The Schlenk flask was sealed and brought out of glovebox.  The reaction was 
stirred for 12 h at 23 ºC before a few drops of ethyl vinyl ether were added.  The solvent was 
removed under reduced pressure.  The residue was purified by flash chromatography 
(hexanes/EtOAc 10:1 to 2:1).  23 (16 mg, 44%) and 24 (8 mg, 31%) was isolated as two products.   
 
Compound 23: 
TLC (2:1 hexanes/EtOAc): Rf= 0.28 (UV).  
1H NMR (400 MHz, CDCl3) δ 7.50 (ddd, J = 6.0, 2.7, 1.0 Hz, 1H), 6.60 (ddt, J = 8.2, 7.0, 1.3 Hz, 
1H), 6.32 (dd, J = 6.0, 1.8 Hz, 1H), 5.53 – 5.43 (m, 2H), 5.41 – 5.31 (m, 2H), 3.89 (quint, J = 6.1 
Hz, 1H), 3.64 (t, J = 6.5 Hz, 2H), 3.45 (ddq, J = 8.4, 4.3, 2.2 Hz, 1H), 2.68 – 2.55 (m, 1H), 2.43 
(ddd, J = 7.7, 6.4, 2.3 Hz, 2H), 2.29 – 2.11 (m, 3H), 2.08 – 1.91 (m, 4H), 1.62 – 1.51 (m, 2H), 
1.48 – 1.36 (m, 2H), 0.94 (t, J = 7.6 Hz, 3H), 0.88 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 196.5, 161.8, 138.9, 135.0, 134.2, 132.7, 132.5, 125.5, 124.4, 
71.7, 62.9, 43.6, 37.0, 35.3, 32.5, 30.8, 27.2, 26.0, 25.9, 20.9, 18.2, 14.3, –4.4, –4.4. 
FTIR (ATR): 3429, 2956, 2928, 2856, 2361, 2327, 1702, 1652, 1580, 1472, 1360, 1251, 1213, 
1066, 1005, 968, 834, 807, 774, 721, 668 cm–1.  
HRMS (FAB+, m/z): calc’d for C26H45O3Si [M+H]+ 433.3132, found: 433.3121. [𝜶]𝑫𝟐𝟑: +136.3° (c = 1.0, C6H6). 
 
Compound 24: 
TLC (2:1 hexanes/EtOAc): Rf= 0.6 (UV).  
1H NMR (400 MHz, CDCl3): δ 7.43 (ddd, J = 5.9, 2.8, 1.0 Hz, 1H), 6.80 (ddt, J = 10.8, 8.8, 1.3 
Hz, 1H), 6.31 (dd, J = 5.9, 1.7 Hz, 1H), 5.76 (q, J = 9.1 Hz, 1H), 5.61 (dddd, J = 11.9, 10.7, 5.2, 
1.2 Hz, 1H), 4.08 – 4.02 (m, 1H), 3.27 (d, J = 9.6 Hz, 1H), 2.38 (dd, J = 9.5, 3.0 Hz, 2H), 2.24 (q, 
J = 11.6 Hz, 2H), 2.17 – 1.95 (m, 2H), 0.91 (s, 9H), 0.11 (s, 3H), 0.08 (s, 3H). 
13C NMR (101 MHz, CDCl3): δ 196.4, 162.3, 141.3, 134.0, 132.4, 130.6, 129.6, 73.1, 44.2, 34.7, 
34.5, 32.6, 26.0, 18.3, –4.6, –4.7. 
FTIR (ATR): 2952, 2926, 2886, 2855, 2359, 2339, 1705, 1654, 1586, 1471, 1369, 1251, 1190, 
1077, 1039, 997, 980, 938, 855, 835, 808, 790, 774, 727, 668 cm–1.  
HRMS (FAB+, m/z): calc’d for C18H29O2Si [M+H]+ 305.1931, found: 305.1942. [𝜶]𝑫𝟐𝟑: –27.8° (c = 0.8, CHCl3) 
 
 
 
 
 
 
 
 
 
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 
 S21 
Preparation of 23 using Ru-2: 
 
 
In a nitrogen-filled glovebox, 22 (64 mg, 0.18 mmol, 1.0 equiv) and 5-hexen-1-ol (142 mg, 1.42 
mmol, 8.0 equiv) were weighed into a 4 mL vial.  THF (0.3 mL) was added to dissolve the 
mixture. Catalyst Ru-2 (24 mg, 20 mol%) was dissolved in THF (0.4 mL) and 0.1 mL of this 
catalyst solution was transferred into the vial.  The vial was sealed with a 14/20 septum and 
brought out of the glovebox.  The reaction was stirred at 40 ºC with a stream of argon (saturated 
with anhydrous THF) bubbling through a needle.  A portion of the catalyst solution (0.1 mL) was 
added into the vial in each 1 hour.  After all the catalyst was added, the reaction mixture was 
continued to stir for 4 h with argon bubbling.  A few drops of ethyl vinyl ether were added, and 
the reaction mixture was concentrated in vacuo.  The residue was purified by column 
chromatography (SiO2, hexanes/EtOAc 2:1) to afford 23 (40 mg, 52%) as a colorless liquid.   
Compund 26 was the proposed by-product (molar ratio of 23:26 was 32:1 as determined by crude 
NMR analysis). 
 
Compound 23: Characterization data were in agreement with previously obtained data. 
Compound 26: Characterization data not available due to the difficulty in separation, mass data 
was obtained by LC-MS (TOF, ES+, m/z): calc’d for C24H41O3Si [M+H]+ 405.2819, found: 
405.2801. 
 
Preparation of D12-prostaglandin J3 (3): 
 
 
 
To a stirred solution of 23 (21.6 mg, 0.05 mmol, 1.0 equiv) in MeCN (0.5 mL) was added 
NMO•H2O (67.5 mg, 0.5 mmol, 10.0 equiv).  Tetrapropylammonium perruthenate (1.8 mg, 5 
µmol, 0.1 equiv) was added until NMO•H2O was fully dissolved and the reaction was stirred at 
23 ºC for 3 hours.  The solution was diluted with Et2O (5 mL), passed through a short pad of 
silica gel, concentrated and was subjected to the next reaction without further purification. 
 
The residue was dissolved in MeCN (1.0 mL) and cooled to 0 ºC.  A solution of hydrofluoric acid 
(48 wt. % in H2O, 0.2 mL) in MeCN (0.4 mL) was added dropwisely.  The solution was stirred in 
the same temperature for 30 min before saturated NaHCO3 solution (1.5 mL) and brine (1.5 mL) 
were added.  The aqueous phase was extracted with EtOAc (5 × 5 mL).  The combined organic 
phase was dried over magnesium sulfate, filtered and concentrated (not to dryness).  The residue 
was purified by flash chromatography (SiO2, CH2Cl2/MeOH 20:1) and through Biotage® SNAP 
Ultra C18 column (H2O/MeOH) to give 3 (10 mg, 60% over 2 steps) as a colorless liquid. 
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TLC (100% EtOAc): Rf= 0.55 (UV).  
1H NMR (400 MHz, CDCl3): δ 7.58 (ddd, J = 6.0, 2.6, 1.0 Hz, 1H), 6.57 (ddt, J = 8.4, 7.0, 1.2 
Hz, 1H), 6.36 (dd, J = 6.0, 1.8 Hz, 1H), 5.69 – 5.60 (m, 1H), 5.60 – 5.45 (m, 2H), 5.45 – 5.35 (m, 
1H), 3.91 (quint, J = 6.8 Hz, 1H), 3.50 – 3.44 (m, 1H), 2.75 (ddd, J = 13.9, 6.9, 4.4 Hz, 1H), 2.68 
– 2.58 (m, 1H), 2.49 (ddd, J = 15.2, 8.4, 7.0 Hz, 1H), 2.36 (t, J = 6.8 Hz, 2H), 2.33 – 2.28 (m, 
2H), 2.20 – 1.98 (m, 5H), 1.68 (quint, J = 7.0 Hz, 2H), 0.96 (t, J = 7.5 Hz, 3H). 
13C NMR (101 MHz, CDCl3): δ 196.4, 175.8, 161.8, 139.9, 136.4, 135.1, 131.7, 131.2, 126.3, 
123.6, 71.1, 44.0, 36.3, 34.5, 32.9, 30.7, 26.6, 24.7, 20.9, 14.4. 
 FTIR (ATR): 3449, 3010, 2956, 2919, 2850, 1728, 1703, 1650, 1579, 1455, 1375, 1222, 1182, 
1046, 959, 838, 809, 721 cm–1.  
HRMS (FAB+, m/z): calc’d for C20H29O4 [M+H]+ 333.2060, found: 333.2060. [𝜶]𝑫𝟐𝟑: +122.6° (c = 0.5, C6H6). 
 
Spectral data (1H NMR, 13C NMR, HRMS) matched with the published data.6  Comparisons of 1H 
NMR data of natural and synthetic D12-prostaglandin J3 (3) are listed in Table S2. 
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Table S2. Comparison of 1H NMR data for D12-prostaglandin J3 (3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
COOH
OH
8
10 12
Me
2
3
4679
11
13
1514 16
17 18
19
20
15
Δ12 -PGJ3 (3)
Proton 
Number  
Natural  D12-PGJ3 1H NMR(Ref.6a) 
600 MHz, CDCl3 1H [δ, multi, J (Hz)]  
This Work, Synthetic D12-PGJ3 1H NMR 
400 MHz, CDCl3 1H [δ, multi, J (Hz)]  
1 n.d.  
2 2.35 (t, J = 7.0 Hz) 2.36 (t, J = 6.8 Hz) 
3 hidden 1.78 – 1.66 (m) 
4 2.02 (m)       2.20 – 2.10 (m) 
5 5.42 (m) 5.60 – 5.51 (m) 
6 hidden 5.51 – 5.45 (m) 
7a 2.64 (m) 2.75 (ddd, J = 13.9, 6.9, 4.4 Hz) 
7b 2.08 (m) 2.20 – 2.10 (m) 
8 3.47 (ddd,  J = 10.0, 4.0, 2.0 Hz) 3.50 – 3.44 (m) 
9 7.56 (ddd,  J = 6.0, 2.0, 1.0 Hz) 7.58 (ddd, J = 6.0, 2.6, 1.0 Hz) 
10 6.35 (dd,  J = 6.0, 2.0 Hz) 6.36 (dd, J = 6.0, 1.8 Hz) 
11 n.d.  
12 n.d.  
13 6.58 (m) 6.57 (ddt, J = 8.4, 7.0, 1.2 Hz) 
14a 2.55 (dt,  J = 15.0, 7.0 Hz) 2.68 – 2.57 (m) 
14b 2.47 (ddd,  J = 15.0, 8.0, 6.0 Hz) 2.49 (ddd, J = 15.2, 8.4, 7.0 Hz) 
15 3.88 (quint,  J = 6.0 Hz) 3.91 (quint, J = 6.8 Hz) 
16 2.28 (m) 2.33 – 2.28 (m) 
17 hidden 5.45 – 5.35 (m) 
18 5.51 (m) 5.69 – 5.60 (m) 
19a 2.00 (m) 2.10 – 1.98 (m) 
19b 1.98 (m)   2.10 – 1.98 (m) 
20 0.96 (t,  J = 7.0 Hz) 0.96 (t, J = 7.5 Hz) 
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4. Synthesis of 15-deoxy-D12,14-prostaglandin J3 (4):  
Synthetic route: 
 
 
 
Preparation of 28: 
 
 
A 25 mL flask was flame dried and charged with CuBr•Me2S (195 mg, 0.95 mmol, 1.9 equiv) and 
LiCl (42 mg, 1.0 mmol, 2.0 equiv) in a nitrogen-filled glove box.  The flask was sealed with 
septum and brought out of glove box, and was heated under vacuum to remove residue water.   
Anhydrous THF (10 mL) was added, and the solution was vigorously stirred for 10 minute at 23 
ºC until a yellow homogeneous solution was formed.  At –78ºC, allyl magnesium bromide (0.9 
mL, 1.0 M solution in THF, 0.9 mmol, 1.8 equiv) was added slowly.  The reaction mixture was 
stirred at –78 ºC for 1 hour and a solution of (R)-6 (198 mg, 1.0 mmol, 2.0 equiv) in THF (1 mL) 
was added slowly.  After 30 minutes stirring at the same temperature, a solution of known 
compound 27 (prepared according to Honda and co-workers7) (62 mg, 0.5 mmol, 1.0 equiv) in 
THF (1 mL) was added slowly.  The reaction was stirred for additional 2 hours at –78 ºC before a 
solution of saturated NH4Cl and NH3•H2O (10 mL, 9:1 NH4Cl/NH3•H2O) was added.  The 
biphasic solution was vigorously stirred until a homogeneous dark blue solution was formed in 
aqueous phase.  The phases were separated and the organic phase was washed with 10 mL 
saturated NH4Cl solution.  The combined aqueous phase was extracted with Et2O (2 × 30 mL). 
The combined organic phase was dried with anhydrous magnesium sulfate, and was concentrated 
in vacuo.  The residue was purified by flash chromatography (SiO2, hexanes/EtOAc 15:1) to give 
a mixture of diasteromers of the aldol products (51 mg, 0.21 mmol). 
 
In a 25 mL flask, the crude aldol product was dissolved in CH2Cl2 (6 mL) and cooled to –10 ºC.  
DMAP (384 mg, 3.15 mmol, 15.0 equiv) and MsCl (49 µL, 0.63 mmol, 3.0 equiv) was added 
sequentially.  The reaction mixture was slowly warmed to 23 ºC and was stirred for 2 h before 
diluted with 10 mL EtOAc and washed with 1 M HCl (10 mL).  The aqueous phase was extracted 
O
BocO
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(36 % yield over 2 steps)(R)-6
O
Me
28
O
Me27
cis-5-octen-1-ol
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with EtOAc (2 × 20 mL).  The combined organic phase was dried with anhydrous magnesium 
sulfate, and was concentrated in vacuo.  The residue was purified by flash chromatography 
(hexanes/EtOAc 15:1) to give 28 (41 mg, 36% yield over 2 steps) as a colorless liquid. 
 
TLC (4:1 hexanes/EtOAc): Rf= 0.56 (UV). 
1H NMR (400 MHz, CDCl3): δ 7.50 (ddd, J = 5.9, 2.6, 1.0 Hz, 1H), 7.03 – 6.90 (m, 1H), 6.36 (dd, 
J = 6.1, 1.8 Hz, 1H), 6.34 – 6.29 (m, 1H), 6.21 (dt, J = 15.1, 6.3 Hz, 1H), 5.79 – 5.66 (m, 1H), 
5.54 (dtt, J = 10.2, 7.2, 1.5 Hz, 1H), 5.37 (dtt, J = 10.5, 7.3, 1.6 Hz, 1H), 5.10 – 5.02 (m, 2H), 
3.60 (ddq, J = 8.5, 4.0, 1.9 Hz, 1H), 3.00 – 2.95 (m, 2H), 2.65 (dddt, J = 13.7, 6.8, 4.2, 1.4 Hz, 
1H), 2.25 (dddt, J = 14.2, 8.8, 7.7, 1.1 Hz, 1H), 2.07 (dquint, J = 7.5, 1.5 Hz, 2H), 0.98 (t, J = 7.5 
Hz, 3H). 
13C NMR (101 MHz, CDCl3): δ 197.5, 160.7, 144.5, 135.4, 135.4, 134.2, 134.1, 131.6, 125.8, 
124.6, 117.9, 43.3, 37.4, 31.2, 20.7, 14.3. 
FTIR (ATR): 3011, 2963, 2931, 2874, 2361, 2335, 1692, 1629, 1579, 1440, 1339, 1280, 1207, 
1100, 989, 915, 872, 839, 729, 668 cm–1.  
HRMS (FAB+, m/z): calc’d for C16H21O [M+H]+ 229.1587, found: 229.1588. [𝜶]𝑫𝟐𝟑: +117.7° (c = 0.5, CHCl3). 
 
Preparation of 29 using Ru-4: 
 
 
 
In a nitrogen-filled glovebox, cis-5-octen-1-ol (205 mg, 1.6 mmol, 8.0 equiv) was dissolved in 
toluene (1 mL) in a 50 mL Schlenk flask and a solution of catalyst Ru-4 (13.6 mg, 16 µmol, 1 
mol%) in THF (0.6 mL) was added.  The Schlenk flask was sealed and brought out of the 
glovebox, and then connected to high vacuum.  The valve was gradually opened (Caution: open 
slowly and stir well to avoid splashing).  After 15 minutes stirring, the flask was refilled with 
argon and sealed, and was brought back into the glovebox.  The residue was diluted with 0.5 mL 
THF, and an aliquot was taken for GC analysis (conversion of homodimerization step was >98% 
by GC analysis).  A solution of 28 (46 mg, 0.2 mmol, 1.0 equiv) in 0.5 mL THF was added into 
the Schlenk flask and an additional 0.4 mL of catalyst solution with Ru-4 (8.5 mg, 10 µmol, 5 
mol%) was added.  The Schlenk flask was sealed and brought out of glovebox.  The reaction was 
stirred for 12 h at 23 ºC before a few drops of ethyl vinyl ether were added.  The solvent was 
removed under reduced pressure.  The residue was purified by column chromatography (SiO2, 
hexanes/EtOAc 2:1).  Compounds 29 (22 mg, 36%) and 30 were separated as a mixture (28 mg, 
molar ratio of 29:30 was 3:1 as determined by crude NMR analysis). 
 
Compound 29: Characterization data not available due to the difficulty in separation. 
Mass data was obtained by LC-MS (TOF, ES+, m/z): calc’d for C20H29O2 [M+H]+ 301.2162, 
found: 301.2080. 
 
O
OH
O
Me
OHcis-5-octen-1-olRu-4 (1 mol%)
   toluene, 23 ºC, 2 torr
then 28, Ru-4 (5 mol%)
THF, 23 ºC 29O
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+
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Compound 30: Characterization data not available due to the difficulty in separation, mass data 
was obtained by LC-MS (TOF, ES+, m/z): calc’d for C18H25O2 [M+H]+ 273.1849, found: 
273.1759. 
 
Preparation of 29 using Ru-2: 
 
 
 
In a nitrogen-filled glovebox, 28 (23 mg, 0.1 mmol, 1.0 equiv) and 5-hexen-1-ol (80 mg, 0.8 
mmol, 8.0 equiv) were weighed into a 4 mL vial.  THF (0.1 mL) was added to dissolve the 
mixture.  Catalyst Ru-2 (13.6 mg, 20 mol%) was dissolved in THF (0.4 mL) and 0.1 mL of this 
catalyst solution was transferred into the vial.  The vial was sealed with a 14/20 septum and 
brought out of the glovebox.  The reaction was stirred at 40 ºC with a stream of argon (saturated 
with anhydrous THF) bubbling through a needle.  A portion of the catalyst solution (0.1 mL) was 
added into the vial in each 1 hour.  After all the catalyst was added, the reaction mixture was 
continued to stir for 2 h with argon bubbling.  A few drops of ethyl vinyl ether was added, and the 
reaction mixture was concentrated in vacuo.  The residue was purified by column 
chromatography (SiO2, hexanes/EtOAc 2:1).  Compounds 29 (9.2 mg, 31%) and 30 were 
separated as a mixture (12 mg, molar ratio of 29:30 was 3:1 as determined by crude NMR 
analysis). 
 
Compound 29: Characterization data not available due to the difficulty in separation. Mass data 
was obtained by LC-MS (TOF, ES+, m/z): calc’d for C20H29O2 [M+H]+ 301.2162, found: 
301.2166. 
 
Compound 30: Characterization data not available due to the difficulty in separation, mass data 
was obtained by LC-MS (TOF, ES+, m/z): calc’d for C18H25O2 [M+H]+ 273.1849, found: 
273.1855. 
 
 
 
Preparation of 15-deoxy-D12,14-prostaglandin J3 (4): 
 
 
Pyridinium chlorochromate (22 mg, 0.1 mmol, 3.0 equiv) was added to a solution of 29 (mixed 
with by-product 30) (10 mg, 0.033 mmol, 1.0 equiv) in CH2Cl2 (0.5 mL) at 23 ºC.  The reaction 
was monitored by TLC and was diluted with Et2O (3 mL) after stirring for 3 h.  The resulting 
solution was filtered through a short pad of silica gel, and was subjected to the next step without 
further purification. 
 
O
OH
O
Me
OH
29O
Me
28 30
+
5-hexen-1-ol
Ru-2 (20 mol%)
THF, 40 ºC
O
Me
OH
1. PCC, CH2Cl2
2. NaClO2, NaH2PO4
2-methyl-2-butene
t-BuOH
(12% yield over 3 steps)
O
Me
COOH
29 4
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 
 S27 
The residue was dissolved in t-BuOH (0.5 mL) at 23 ºC, and 2-methyl-2-butene (35 μL, 0.33 
mmol, 10 equiv), a solution of NaH2PO4•H2O (6.9 mg, 0.05 mmol, 1.5 equiv) in H2O (0.12 mL) 
and a solution of NaClO2 (80 %, 5.6 mg, 0.05 mmol, 1.5 equiv) in H2O (0.12 mL) was added 
sequentially.  After stirring at 23 ºC for 30 minutes, the reaction mixture was diluted with a 
solution of NaH2PO4•H2O (108 mg) in H2O (2 mL) and extracted with EtOAc (5 × 5 mL).  The 
combined organic extracts were dried over anhydrous magnesium sulfate, filtered, and 
concentrated under reduced pressure.  Flash column chromatography (SiO2, CH2Cl2/MeOH 20:1) 
and purification through Biotage® SNAP Ultra C18 column (H2O/MeOH) afforded pure 
compound 4 (4 mg, 0.013 mmol, 12% yield from 28) as a colorless oil.  
 
TLC (10:1 CH2Cl2/MeOH): Rf= 0.44 (UV). 
1H NMR (500 MHz, CDCl3): δ 7.48 (ddd, J = 6.1, 2.6, 1.0 Hz, 1H), 6.96 (d, J = 11.5 Hz, 1H), 
6.42 – 6.31 (m, 2H), 6.22 (dt, J = 14.9, 6.3 Hz, 1H), 5.57 – 5.51 (m, 1H), 5.50 – 5.43 (m, 1H), 
5.37 (dtt, J = 10.1, 6.8, 1.7 Hz, 2H), 3.64 – 3.55 (m, 1H), 2.98 (t, J = 6.8 Hz, 2H), 2.60 (dt, J = 
12.3, 5.9 Hz, 1H), 2.43 – 2.25 (m, 3H), 2.12 – 2.00 (m, 4H), 1.69 (quint, J = 7.4 Hz, 2H), 0.99 (t, 
J = 7.5 Hz, 3H). 
13C NMR (101 MHz, CDCl3): δ 197.6, 176.6, 160.9, 144.5, 135.5, 135.5, 134.2, 131.6, 131.5, 
126.1, 125.8, 124.6, 43.6, 33.0, 31.2, 30.9, 26.7, 24.6, 20.7, 14.3. 
FTIR (ATR): 3010, 2960, 2926, 2874, 2854, 1710, 1693, 1626, 1578, 1512, 1455, 1208, 1154, 
1087, 1024, 977, 817, 728 cm–1.  
HRMS (FAB+, m/z): calc’d for C20H27O3 [M+H]+ 315.1955, found: 315.1968. [𝜶]𝑫𝟐𝟑: +129.6° (c = 0.07, C6H6). 
 
Spectral data (1H NMR, 13C NMR, HRMS) matched with the published data.8 
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13C NMR (101 MHz, CDCl3) of compound 8a. 
 
 
19F NMR (282 MHz, CDCl3) of compound 8a. 
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13C NMR (101 MHz, CDCl3) of compound 8b. 
 
 
19F NMR (282 MHz, CDCl3) of compound 8b. 
 
020406080100120140160180200
ppm
1
4
.1
2
2
.6
2
4
.6
3
1
.6
3
3
.3
3
8
.5
5
5
.7
7
6
.7
8
4
.2
8
4
.5
8
4
.8
8
5
.0
1
1
8
.5
1
1
9
.2
1
2
2
.1
1
2
4
.9
1
2
7
.5
1
2
7
.8
1
2
8
.4
1
2
9
.6
1
3
2
.6
1
3
3
.4
1
6
6
.4
C
D
C
l 3
 –
7
7
.1
6
-180-160-140-120-100-80-60-40-20020
ppm
-7
1
.3
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S35 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
9.
 
 
OT
BS
M
e
9
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
6.73
12.90
8.57
2.09
1.02
2.04
1.00
0.05
0.05
0.87
0.88
0.88
0.88
0.89
0.89
0.90
0.90
0.91
1.25
1.26
1.26
1.26
1.27
1.27
1.27
1.27
1.28
1.28
1.28
1.29
1.29
1.29
1.30
1.30
1.31
1.32
1.32
1.34
1.40
1.41
1.42
1.42
1.42
1.42
1.43
1.43
2.19
2.20
2.20
2.21
2.21
2.21
2.22
2.22
2.23
3.67
3.68
3.70
5.01
5.01
5.01
5.03
5.03
5.03
5.04
5.05
5.05
5.06
5.79
5.81
5.83
CDCl
3
 – 7.26
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S36 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
9.
 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
-4.4
-4.2
14.2
18.3
22.8
25.2
26.1
32.2
37.0
42.1
72.2
116.7
135.7
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
  S37 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
10
. 
 
O
OT
BS
M
e
10
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
6.37
12.59
6.06
1.81
2.00
1.00
1.00
0.05
0.05
0.07
0.07
0.86
0.86
0.86
0.86
0.87
0.87
0.88
0.88
0.89
0.89
0.90
0.90
1.25
1.27
1.28
1.28
1.28
1.28
1.29
1.30
1.30
1.31
1.31
1.31
1.32
1.32
1.32
1.33
1.33
1.34
1.50
1.50
1.50
1.50
1.52
1.53
1.53
1.54
1.54
1.54
1.57
2.50
2.50
2.51
2.51
2.51
2.52
2.52
2.52
4.16
4.16
4.17
4.18
4.19
9.80
9.81
9.81
9.81
9.82
9.82
CDCl
3
 – 7.26
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S38 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
10
. 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
-4.5
-4.3
14.2
18.1
22.7
25.0
25.9
31.9
38.0
51.0
68.4
202.7
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S39 
  
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
(R
)-6
. 
 
O
Bo
cO (R
)-6
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
9.35
1.04
1.05
1.00
0.99
1.00
1.49
2.36
2.37
2.41
2.42
2.79
2.80
2.84
2.85
5.69
5.69
5.69
5.70
5.70
5.70
5.71
5.71
5.71
5.71
5.72
6.31
6.31
6.32
6.33
7.58
7.58
7.59
7.60
CDCl
3
 – 7.26
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S40 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
( R
) -6
. 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
27.8
41.1
74.3
83.4
137.3
152.8
158.7
204.7
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S41 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
11
. 
 
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
5.78
12.64
8.32
1.04
2.10
1.02
1.04
1.06
2.08
1.02
1.00
1.03
1.04
0.05
0.05
0.86
0.86
0.87
0.87
0.88
0.89
0.89
0.90
1.24
1.25
1.25
1.26
1.26
1.26
1.26
1.27
1.27
1.27
1.28
1.28
1.28
1.29
1.29
1.30
1.30
1.30
1.31
1.42
1.43
1.43
1.44
1.45
2.40
2.41
2.41
2.42
2.43
2.43
2.43
2.43
2.43
3.84
5.05
5.05
5.06
5.06
5.08
5.09
5.09
5.09
6.33
6.33
6.34
6.35
6.61
6.61
7.51
7.51
7.52
7.52
7.53
7.53
CDCl
3
 – 7.26
O
M
e
OT
BS 11
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S42 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
11
. 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
-4.5
-4.2
14.2
18.2
22.8
25.1
26.0
32.0
37.1
37.4
43.1
71.7
117.8
132.8
134.3
135.1
138.5
161.4
196.5
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S43 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
14
. 
 
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
6.23
12.32
5.12
6.00
2.19
2.10
0.99
2.11
1.01
1.03
2.10
1.05
1.07
1.04
1.00
1.02
1.03
0.04
0.05
0.87
1.24
1.24
1.25
1.25
1.25
1.26
1.26
1.26
1.27
1.27
1.27
1.28
1.28
1.28
1.29
1.29
1.29
1.30
1.39
1.39
1.39
1.41
1.41
1.42
1.42
1.43
1.43
1.43
1.44
1.44
1.45
1.45
1.45
1.54
1.54
1.56
1.56
1.56
1.56
1.58
1.58
2.02
2.03
2.04
2.41
2.42
2.43
2.43
2.44
2.44
3.62
3.63
3.65
3.84
6.32
6.32
6.33
6.34
6.59
7.49
7.50
CDCl
3
 – 7.26
O
M
e
OT
BS
OH
14
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S44 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
14
. 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
-4.5
-4.2
14.2
18.2
22.8
25.1
25.8
26.0
27.2
30.7
32.0
32.5
37.5
37.5
43.6
62.9
71.7
125.4
132.5
132.7
135.0
138.8
161.8
196.5
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S45 
    
 1 H
 N
M
R 
(5
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
1.
 
 
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
3.39
5.44
3.50
2.12
2.95
2.00
1.20
0.95
0.97
1.04
1.02
2.04
0.98
1.00
1.00
0.88
0.89
0.90
0.91
1.28
1.28
1.29
1.30
1.30
1.30
1.30
1.31
1.31
1.32
1.32
1.32
1.32
1.33
1.33
1.33
1.34
1.34
1.48
1.49
1.50
1.50
1.69
1.69
1.70
1.70
1.70
1.71
1.71
2.10
2.10
2.11
2.12
2.12
2.13
2.13
2.14
2.14
2.34
2.36
2.37
2.47
2.49
2.56
5.44
5.48
6.35
6.35
6.36
6.36
6.58
6.58
7.56
7.56
7.56
7.57
7.57
7.57
7.58
7.58
CDCl
3
 – 7.26
O
M
e
OH
CO
OH
1
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S46 
  
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
14.2
22.8
24.6
25.4
26.6
30.6
31.9
33.1
36.7
37.3
43.9
71.5
126.2
131.7
131.8
135.0
139.8
162.0
177.3
196.6
CDCl
3
 –77.16
 13
C 
N
M
R 
(1
26
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
1.
 
 
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S47 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
16
. 
 
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
3.34
4.63
2.57
3.33
1.16
1.05
2.15
1.02
2.05
1.19
1.00
1.04
0.86
0.89
0.91
1.27
1.28
1.29
1.30
1.31
1.31
1.32
1.33
1.33
1.42
1.43
1.45
1.45
1.47
1.47
2.18
2.20
2.21
2.22
2.22
2.23
2.23
2.24
2.25
2.26
2.27
5.03
5.03
5.04
5.04
5.04
5.05
5.07
5.08
5.08
5.09
6.22
6.24
6.26
6.26
6.30
6.30
6.30
6.34
6.34
6.36
6.36
6.93
6.94
6.94
6.97
6.97
6.98
7.48
7.48
7.49
7.49
7.50
7.50
7.51
7.51
CDCl
3
 – 7.26
O
M
e
16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S48 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
16
. 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
2
2
0
p
p
m
14.1
22.6
28.6
31.5
33.6
37.4
43.2
117.8
125.7
131.8
134.3
134.9
135.4
147.1
160.6
197.5
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S49 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
17
. 
 
O
M
eOH
17
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
3.16
4.05
5.19
2.51
2.13
1.98
1.32
1.00
0.98
2.32
1.06
1.01
1.90
1.13
1.00
1.03
0.88
0.89
0.90
0.91
1.29
1.30
1.30
1.31
1.31
1.32
1.32
1.32
1.32
1.33
1.38
1.38
1.39
1.40
1.40
1.41
1.41
1.42
1.42
1.42
1.44
1.44
1.45
1.47
1.53
1.53
1.54
1.55
1.55
1.55
1.57
1.57
2.00
2.01
2.02
2.02
2.21
2.21
2.23
2.23
3.61
3.63
3.64
6.25
6.29
6.32
6.34
6.34
6.35
6.36
6.93
6.96
7.46
7.47
7.47
7.47
7.48
7.48
7.49
7.49
CDCl
3
 – 7.26
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S50 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
17
. 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
14.2
22.6
25.8
27.2
28.6
30.9
31.5
32.5
33.6
43.7
62.9
125.3
125.8
131.8
132.6
135.3
135.4
147.0
160.9
197.6
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S51 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
2.
 
 
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
3.74
4.23
2.29
2.41
2.29
5.61
0.99
1.04
2.24
1.94
1.14
1.08
1.00
0.88
0.89
0.90
0.91
1.28
1.29
1.29
1.29
1.30
1.30
1.31
1.31
1.32
1.32
1.33
1.33
1.33
1.34
1.43
1.44
1.44
1.45
1.47
1.66
1.68
1.70
1.70
1.70
2.04
2.06
2.21
2.22
2.23
2.25
2.25
2.25
2.31
2.33
2.35
5.45
6.25
6.27
6.29
6.29
6.32
6.35
6.35
6.36
6.37
6.37
6.94
6.94
6.94
6.97
6.97
6.97
7.46
7.46
7.46
7.47
7.47
7.48
7.48
7.48
CDCl
3
 – 7.26
O
M
e
CO
OH
2
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S52 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
2.
 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
14.2
22.6
24.6
26.7
28.6
30.8
31.6
33.2
33.6
43.6
125.8
126.2
131.5
131.9
135.1
135.5
147.2
160.8
177.9
197.6
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S53 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
18
. 
 
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
3.15
0.95
1.06
1.04
1.06
4.22
1.03
1.03
2.04
1.00
1.86
1.86
1.87
1.88
1.88
1.89
1.90
1.90
1.90
2.01
2.02
2.09
2.10
2.11
2.13
2.18
2.20
2.20
2.21
2.22
2.22
2.23
2.26
2.27
2.27
2.28
2.29
2.81
2.84
2.84
2.85
2.85
2.86
2.87
2.87
2.88
2.88
2.88
2.89
2.91
2.91
2.92
3.99
4.25
4.26
4.26
4.28
5.11
5.12
5.12
5.12
5.12
5.13
5.15
5.15
5.15
5.15
5.16
5.16
5.16
5.77
5.79
5.80
5.82
CDCl
3
 – 7.26
S
S
OH
18
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S54 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
18
. 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
26.0
30.2
30.5
42.1
42.2
44.3
67.6
118.7
134.2
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S55 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
19
. 
 
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
3.21
3.38
9.28
2.29
1.06
1.19
2.11
4.51
1.05
1.10
2.07
1.00
0.07
0.09
0.88
1.78
1.80
1.80
1.80
1.82
1.86
1.87
2.07
2.07
2.08
2.11
2.21
2.21
2.21
2.22
2.22
2.22
2.23
2.23
2.23
2.24
2.24
2.25
2.25
2.25
2.76
2.77
2.77
2.79
2.79
2.80
2.81
2.82
2.82
2.83
2.84
2.84
2.85
2.87
2.87
3.99
3.99
4.00
4.01
4.02
4.06
4.08
4.08
4.10
5.02
5.02
5.03
5.05
5.05
5.05
5.06
5.73
5.75
5.76
5.78
5.80
CDCl
3
 – 7.26
S
S
OT
BS
19
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S56 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
19
. 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
-4.5
-4.3
18.2
26.0
26.2
30.1
30.7
42.3
42.3
44.1
68.1
117.6
134.3
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S57 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
20
. 
 
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
3.19
3.24
9.21
2.09
2.20
0.99
1.99
1.00
1.10
0.06
0.08
0.87
2.29
2.29
2.30
2.30
2.31
2.31
2.32
2.32
2.52
2.52
2.53
2.53
2.53
2.53
2.54
2.54
2.54
4.23
4.25
4.26
4.28
4.29
5.05
5.06
5.06
5.06
5.06
5.07
5.08
5.08
5.08
5.08
5.09
5.09
5.09
5.10
5.10
5.10
5.11
5.11
5.11
5.73
5.75
5.75
5.76
5.77
5.77
5.77
5.79
5.79
5.80
5.81
5.82
5.82
5.83
9.79
9.79
9.80
9.80
9.80
9.81
CDCl
3
 – 7.26
OT
BS
O
20
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S58 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
20
. 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
-4.7
-4.2
18.1
25.9
42.5
50.5
67.9
118.3
133.9
202.3
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S59 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
21
. 
 
OT
BS
O
M
e
21
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
2.99
2.90
8.99
3.13
2.17
2.01
1.94
0.96
1.01
1.00
0.95
0.06
0.08
0.87
0.94
0.96
0.97
2.00
2.00
2.01
2.01
2.01
2.02
2.02
2.03
2.04
2.04
2.06
2.26
2.26
2.26
2.27
2.28
2.28
2.28
2.29
2.29
2.29
2.29
2.29
2.30
2.30
2.30
2.30
2.30
2.31
2.31
2.31
2.32
2.32
2.32
2.50
2.50
2.51
2.52
4.20
4.21
4.22
4.22
4.23
4.24
5.31
5.31
5.31
5.33
5.33
5.34
5.48
5.48
5.49
5.50
5.51
9.79
9.80
9.80
CDCl
3
 – 7.26
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S60 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
21
. 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
-4.7
-4.2
14.3
18.1
20.9
25.9
35.7
50.6
68.3
123.7
134.8
202.4
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S61 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
22
. 
 
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
5.72
9.11
3.17
2.02
3.08
1.99
0.99
0.94
1.02
2.02
1.01
1.03
0.99
0.98
1.00
1.00
0.05
0.06
0.85
0.87
0.87
0.88
0.92
0.93
0.95
1.98
2.00
2.00
2.00
2.02
2.02
2.02
2.17
2.18
2.22
2.23
2.23
2.23
2.23
2.24
2.24
2.24
2.25
2.26
2.40
2.42
2.42
2.43
2.44
3.87
3.88
3.90
5.04
5.04
5.04
5.05
5.05
5.05
5.05
5.07
5.08
5.08
5.08
5.38
5.46
6.32
6.32
6.33
6.34
6.60
6.61
6.61
7.50
7.50
7.51
7.51
7.52
7.52
7.52
7.53
CDCl
3
 – 7.26
O
OT
BS
M
e
22
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S62 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
22
. 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
-4.4
-4.4
14.3
18.2
20.9
26.0
35.3
36.9
37.1
43.1
71.7
117.7
124.4
132.7
134.1
134.4
135.1
138.6
161.4
196.4
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S63 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
23
. 
 
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
6.01
8.86
2.96
2.37
2.35
4.12
3.24
2.08
0.97
0.97
2.07
1.00
1.98
2.00
0.99
1.00
1.00
0.05
0.06
0.85
0.88
0.92
0.94
0.95
1.39
1.40
1.41
1.41
1.42
1.43
1.43
1.54
1.55
1.56
1.56
1.56
1.56
1.57
1.58
1.58
1.60
1.60
1.98
1.99
2.00
2.00
2.02
2.02
2.03
2.04
2.22
2.22
2.23
2.24
2.24
2.24
2.41
2.42
2.43
2.43
2.43
2.44
2.45
3.62
3.64
3.65
3.89
5.46
5.46
5.48
5.48
6.31
6.32
6.33
6.33
6.59
6.60
7.49
7.49
7.50
7.51
CDCl
3
 – 7.26
23
O
OT
BS
OH M
e
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S64 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
23
. 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
-4.4
14.3
18.2
20.9
25.9
26.0
27.2
30.8
32.5
35.3
37.0
43.6
62.9
71.7
124.4
125.5
132.5
132.7
134.2
135.0
138.9
161.8
196.5
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S65 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
24
. 
 
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
3.20
3.04
9.54
1.30
1.04
2.19
2.07
0.94
1.00
0.99
0.97
0.98
0.95
1.00
0.08
0.11
0.91
2.01
2.03
2.04
2.04
2.05
2.09
2.12
2.14
2.20
2.23
2.24
2.25
2.26
2.29
2.37
2.37
2.38
2.39
2.40
3.26
3.29
4.03
4.04
4.04
4.05
4.06
4.07
4.07
5.60
5.60
5.61
5.61
5.62
5.63
5.63
5.64
5.65
5.75
5.77
6.30
6.30
6.31
6.32
6.77
6.77
6.78
6.79
6.79
6.80
6.80
6.81
6.82
6.82
7.42
7.42
7.42
7.43
7.43
7.43
7.44
7.44
CDCl
3
 – 7.26
O
OT
BS
24
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S66 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
24
. 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
-4.7
-4.6
18.3
26.0
32.6
34.5
34.7
44.2
73.1
129.6
130.6
132.4
134.0
141.3
162.3
196.4
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S67 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
3.
 
 
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
3.21
2.62
4.83
1.98
2.21
1.02
0.81
0.84
1.02
1.00
1.15
2.33
1.06
1.10
0.97
0.99
0.95
0.96
0.98
1.69
1.69
1.70
1.70
1.71
1.71
1.72
1.72
1.72
1.73
1.73
1.74
2.04
2.05
2.05
2.06
2.07
2.07
2.08
2.08
2.09
2.12
2.14
2.16
2.30
2.30
2.30
2.30
2.31
2.31
2.32
2.32
2.32
2.32
2.34
2.34
2.35
2.36
2.36
2.37
2.49
5.47
5.48
5.48
5.49
5.49
5.50
6.35
6.35
6.36
6.37
6.57
6.58
7.57
7.57
7.58
7.58
7.59
7.59
7.59
7.60
CDCl
3
 – 7.26
3
O
OH
CO
OH M
e
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S68 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
3.
 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
14.4
20.9
24.7
26.6
30.7
32.9
34.5
36.3
44.0
71.1
123.6
126.3
131.2
131.7
135.1
136.4
139.9
161.8
175.8
196.4
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S69 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
28
. 
 
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
2.96
1.96
1.09
0.98
1.85
0.95
2.06
0.92
0.93
1.01
0.96
0.83
1.03
0.97
1.00
0.96
0.98
1.00
2.04
2.05
2.05
2.05
2.06
2.07
2.08
2.09
2.09
2.23
2.26
2.27
2.96
2.96
2.98
2.99
2.99
3.59
5.04
5.04
5.04
5.05
5.05
5.05
5.05
5.08
5.08
5.08
5.36
5.38
5.39
5.53
5.55
6.20
6.22
6.23
6.25
6.29
6.30
6.30
6.32
6.33
6.33
6.33
6.35
6.35
6.36
6.37
6.95
6.96
6.96
6.98
6.98
7.49
7.49
7.50
7.50
7.51
7.51
7.51
7.51
CDCl
3
 – 7.26
O
M
e
28
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S70 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
28
. 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
14.3
20.7
31.2
37.4
43.3
117.9
124.6
125.8
131.6
134.1
134.2
135.4
135.4
144.5
160.7
197.5
CDCl
3
 –77.16
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S71 
    
 1 H
 N
M
R 
(4
00
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
4.
 
 
-1
0
1
2
3
4
5
6
7
8
9
1
0
p
p
m
3.36
2.32
4.34
3.44
1.31
2.00
1.12
1.93
1.39
1.02
1.00
2.22
0.98
1.14
0.97
0.99
1.00
1.67
1.68
1.69
1.70
1.70
1.72
2.04
2.05
2.06
2.06
2.07
2.07
2.08
2.08
2.09
2.09
2.32
2.34
2.34
2.35
2.36
2.97
2.98
3.00
5.36
5.37
5.37
5.37
5.38
5.38
5.38
5.38
5.39
5.39
5.45
5.45
5.47
5.53
5.55
6.21
6.24
6.31
6.32
6.34
6.34
6.35
6.35
6.36
6.37
6.37
6.37
6.95
6.97
7.47
7.47
7.47
7.47
7.48
7.48
7.48
7.49
CDCl
3
 – 7.26
O
M
e
CO
OH
4
Li, Ahmed, Xu, Stoltz, and Grubbs  Supporting Information 
 S72 
  
 13
C 
N
M
R 
(1
01
 M
H
z,
 C
D
Cl
3) 
of
 c
om
po
un
d 
4.
 
 
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
1
4
0
1
6
0
1
8
0
2
0
0
p
p
m
14.3
20.7
24.6
26.7
30.9
31.2
33.0
43.6
124.6
125.8
126.1
131.5
131.6
134.2
135.5
135.5
144.5
160.9
176.6
197.6
CDCl
3
 –77.16
